News

SINGAPORE, June 11, 2026 /PRNewswire/ -- DKSH entered a strategic distribution partnership with BridgeBio to support regulatory evaluation and potential patient…

Higher blood levels of fibroblast growth factor 23 (FGF23) — a bone-derived hormone — are associated with higher levels of established markers of heart damage and…

AbstractBackground: Advances in diagnostic criteria for transthyretin cardiac amyloidosis (ATTR-CM) and expanded insurance coverage for bone scintigraphy have…

AbstractObjectiveTo assess the neuropathic burden and quality-of-life impact in patients with wild-type transthyretin amyloidosis (wtATTR) using standardized…

Efficacy of acoramidis in transthyretin amyloid cardiomyopathy with and without atrial fibrillation: results from ATTRibute-CM. (Top) In this post hoc analysis of…

AbstractTransthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) is a restrictive cardiac disease caused by the deposition of TTR in the heart. TTR is synthesized by…

At AstraZeneca, we turn ideas into life-changing medicines. Working here means being entrepreneurial, thinking big, and collaborating to make the impossible a…

AbstractTransthyretin amyloidosis (ATTR) is a multisystemic disorder associated with extracellular accumulation of misfolded transthyretin (TTR) protein forming…

Improved evaluation strategies are needed to recognize transthyretin cardiac amyloidosis (ATTR-CM) faster in patients presenting with heart failure (HF), especially…

AbstractFrontline therapy for systemic amyloid light chain (AL) amyloidosis has evolved significantly with the approval of daratumumab in combination with…